Home » Newsletters » BioWorld Science

BioWorld Science

July 13, 2017

View Archived Issues

Carmell Therapeutics closes series B financing

Two novel mutations in RASGRP2 gene tied to bleeding diathesis

FDA accepts Axium Pharmaceuticals' orphan drug request for Truveta

Erytech collaborates with Queen's University on eryminase in arginase-1 deficiency

Regen BioPharma announces discovery of new dynamic compound series that modulates NR2F6

Shire develops enhanced factor IX gene therapy

Neurofilament light polypeptide in plasma as a potential biomarker in Huntington's disease

UCL Business discloses compounds useful for treating cancer

Sichuan Kelun-Biotech Biopharmaceutical divulges PARP inhibitors

Jiangsu Hengrui Medicine and collaborator identify SERDs

ADT Pharmaceuticals patents RAS GTPases inhibitors

Meissa Vaccines awarded NIH grant to support IND for RSV vaccine

Merck & Co. and Alectos Therapeutics present OGA inhibitors

FDA grants orphan drug designation to MNK-1411 for Duchenne muscular dystrophy

FDA advisory committee recommends approval of CTL-019 for young patients with B-cell ALL

Lupin identifies PI3K inhibitors

Avelas opens phase II study of AVB-620 for detection of malignant tissue in breast cancer

Novartis divulges Raf kinase inhibitors

Korea first to approve Invossa-K cell and gene therapy for degenerative arthritis

Thermo Fisher Scientific and SRI International collaborate on small molecule research

First-in-human results with UCB-7665 lead to further trials

Results from phase I trial of oral CR-845 in hemodialysis patients with CKD

ViaCyte begins clinical testing of VC-02 combination product for type 1 diabetes

Durect's 25-HC3S receives orphan designation from the FDA

GSK initiates phase II study of GSK-2330811 in diffuse cutaneous systemic sclerosis

Amgen reports final analysis from ASPIRE trial of Kyprolis in relapsed multiple myeloma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...